Rising Infectious Diseases Fueling Growth In The Anthrax Vaccine Market Is Supporting Development Across The Anthrax Vaccine Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Will Be The Estimated Market Size Of The Anthrax Vaccine Market By 2030?

The anthrax vaccine market size has demonstrated consistent growth in recent years. It is anticipated to expand from a valuation of $11.77 billion in 2025 to $12.33 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 4.7%. The expansion observed in previous periods is attributable to the widespread presence of anthrax among livestock, vaccination programs organized by governments, advancements in immunology research, certain limitations in vaccine production capacity, and a heightened understanding of risks associated with occupational exposure.

The anthrax vaccine market is anticipated to experience consistent expansion over the upcoming years. This market is projected to reach $14.49 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.1%. This growth during the projection period stems from factors such as the creation of recombinant and next-generation vaccines, an increasing need for both human and animal prophylaxis, progress in vaccine delivery systems, the broadening of biodefense initiatives, and partnerships between pharmaceutical companies and defense agencies. Key trends for the forecast period encompass refined vaccine formulations, extended immunization campaigns, breakthroughs in cold chain and storage, improved biodefense and pandemic readiness, and vaccination efforts led by governments and militaries.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp

What Major Growth Factors Are Impacting The Anthrax Vaccine Market?

The increasing occurrence of infectious diseases is projected to drive the expansion of the anthrax vaccine market in the future. These diseases are health conditions stemming from pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, which can transmit directly or indirectly between individuals. Symptoms can range from mild to severe, and in some cases, be fatal, depending on the pathogen and the individual’s immune response. The widespread presence of infectious diseases is attributed to global demographic shifts, urbanization, changes in environment and land use, and evolving human behavior. The anthrax vaccine is primarily administered for protection against anthrax, and investigations into its immunogenic properties and adaptability are exploring its potential for broader application in preventing other infectious diseases. For instance, in February 2023, the Council on Foreign Relations, a US-based nonprofit organization, reported that up to 75% of newly identified or emerging infectious diseases (EIDs) and 60% of known infectious diseases originated from animals. Moreover, zoonoses worldwide lead to 2.7 million human deaths and 2.5 billion disease episodes in people annually. Thus, the growing prevalence of diseases is a key factor propelling the anthrax vaccine market’s growth.

How Is The Anthrax Vaccine Market Distributed Across Key Segments?

The anthrax vaccine market covered in this report is segmented –

1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine

2) By Application Type: Animal Use, Human Use

3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels

Subsegments:

1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine

2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine

Which Trends Are Influencing The Direction Of The Anthrax Vaccine Market?

Leading companies within the anthrax vaccine market are concentrating on developing innovative products and obtaining FDA approvals for their vaccines to ensure safety, efficacy, and availability for individuals at risk of anthrax exposure. Such FDA endorsement guarantees that a vaccine has undergone rigorous testing in clinical trials and is proven safe for public use, thereby shielding individuals from potential adverse effects. A notable instance occurred in July 2023, when Emergent BioSolutions Inc., a US-based biopharmaceutical company, received approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), formerly identified as AV7909, from the U.S. Food and Drug Administration (FDA). This approval was contingent upon information from a Phase 2 trial assessing Cyfendus’s non-interference with antibacterial medications and Phase 3 clinical research comparing the immunogenicity and safety of the vaccine to BioThrax, the previous anthrax vaccine. Furthermore, the imperative lies in creating safer and more effective adjuvants to address reactogenicity-related challenges and enhance the general efficiency of anthrax vaccines.

Who Are The Prominent Players Across The Anthrax Vaccine Market?

Major companies operating in the anthrax vaccine market are Emergent BioSolutions Inc., Indian Immunologicals Limited, GC Biopharma, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company Inc., Botswana Vaccine Institute, VECOL S.A., Biological E Limited, Serum Institute of India Pvt. Ltd., Panacea Biotec Ltd., China National Biotec Group, Sinovac Biotech Ltd., Instituto Butantan, Razi Vaccine and Serum Research Institute, Federal State Unitary Enterprise Microgen, KM Biologics Co. Ltd., Haffkine Bio-Pharmaceutical Corporation Ltd.

Access The Complete Anthrax Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

Which Region Is The Dominant Market In The Anthrax Vaccine Market?

North America was the largest region in the anthrax vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Anthrax Vaccine Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp

Browse Through More Reports Similar to the Global Anthrax Vaccine Market 2026, By The Business Research Company

Anthrax Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

Anthrax Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

Anthracycline Market Report 2026

https://www.thebusinessresearchcompany.com/report/anthracycline-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795